Als donateur kunt u korting krijgen bij verschillende bedrijven, waaronder bij Medpro voor o.a. prostasol  een veelgebruikt natuurlijk middel bij prostaatkanker als alternatief voor hormoontherapie.

Of u kunt een urinetest laten doen bij oplopende PSA.  

3 januari 2022: Bron The Lancet

Bij mannen met hoogrisico niet uitgezaaide prostaatkanker geeft een combinatietherapie met abiraterone  en hormoontherapie (androgeen deprivatie therapie - ADT)  -  een verbeterde metastasevrije overleving vergeleken met hormoontherapie alleen. Aldus een analyse samengenomen van twee fase III trials.

Mannen die bij de diagnose prostaatkanker een stadium 3/4 hebben en een Gleasonscore van 8 tot 10 , maar nog geen zichtbaar aantoonbare uitzaaiingen worden gezien als hoog risicopatiënten voor uitzaaiingen. Bijna altijd wordt deze patiënten een combintatiebehandeling aangeraden van bestraling plus hormoontherapie plus eventueel abiraterone of apalutamide of enzalutamide

Een meta-analyse van fase III studies laat zien dat bij mannen met hoogrisico niet-gemetastaseerde prostaatkanker een combinatietherapie met abiraterone en hormoontherapie geassocieerd was met verbeterde metastasevrije overleving vergeleken met hormoontherapie alleen, hoewel het combineren van abiraterone met enzalutamide geen voordeel lijkt op te leveren.

Volgens de onderzoekers moet Abirateronacetaat met prednison worden beschouwd als een nieuwe standaardbehandeling voor deze groep van prostaatkankerpatiënten.

Hier het abstract van de studie. Voor het volledige studierapport moet worden betaald:

Abiraterone acetate and prednisolone with or without enzalutamide for high-risk non-metastatic prostate cancer: a meta-analysis of primary results from two randomised controlled phase 3 trials of the STAMPEDE platform protocol

Published:December 23, 2021DOI:



Men with high-risk non-metastatic prostate cancer are treated with androgen-deprivation therapy (ADT) for 3 years, often combined with radiotherapy. We analysed new data from two randomised controlled phase 3 trials done in a multiarm, multistage platform protocol to assess the efficacy of adding abiraterone and prednisolone alone or with enzalutamide to ADT in this patient population.


These open-label, phase 3 trials were done at 113 sites in the UK and Switzerland. Eligible patients (no age restrictions) had high-risk (defined as node positive or, if node negative, having at least two of the following: tumour stage T3 or T4, Gleason sum score of 8–10, and prostate-specific antigen concentration ≥40 ng/mL) or relapsing with high-risk features (≤12 months of total ADT with an interval of ≥12 months without treatment and PSA concentration ≥4 ng/mL with a doubling time of <6 months, or a PSA concentration ≥20 ng/mL, or nodal relapse) non-metastatic prostate cancer, and a WHO performance status of 0–2. Local radiotherapy (as per local guidelines, 74 Gy in 37 fractions to the prostate and seminal vesicles or the equivalent using hypofractionated schedules) was mandated for node negative and encouraged for node positive disease. In both trials, patients were randomly assigned (1:1), by use of a computerised algorithm, to ADT alone (control group), which could include surgery and luteinising-hormone-releasing hormone agonists and antagonists, or with oral abiraterone acetate (1000 mg daily) and oral prednisolone (5 mg daily; combination-therapy group). In the second trial with no overlapping controls, the combination-therapy group also received enzalutamide (160 mg daily orally). ADT was given for 3 years and combination therapy for 2 years, except if local radiotherapy was omitted when treatment could be delivered until progression. In this primary analysis, we used meta-analysis methods to pool events from both trials. The primary endpoint of this meta-analysis was metastasis-free survival. Secondary endpoints were overall survival, prostate cancer-specific survival, biochemical failure-free survival, progression-free survival, and toxicity and adverse events. For 90% power and a one-sided type 1 error rate set to 1·25% to detect a target hazard ratio for improvement in metastasis-free survival of 0·75, approximately 315 metastasis-free survival events in the control groups was required. Efficacy was assessed in the intention-to-treat population and safety according to the treatment started within randomised allocation. STAMPEDE is registered with ClinicalTrials.govNCT00268476, and with the ISRCTN registry, ISRCTN78818544.


Between Nov 15, 2011, and March 31, 2016, 1974 patients were randomly assigned to treatment. The first trial allocated 455 to the control group and 459 to combination therapy, and the second trial, which included enzalutamide, allocated 533 to the control group and 527 to combination therapy. Median age across all groups was 68 years (IQR 63–73) and median PSA 34 ng/ml (14·7–47); 774 (39%) of 1974 patients were node positive, and 1684 (85%) were planned to receive radiotherapy. With median follow-up of 72 months (60–84), there were 180 metastasis-free survival events in the combination-therapy groups and 306 in the control groups. Metastasis-free survival was significantly longer in the combination-therapy groups (median not reached, IQR not evaluable –NE) than in the control groups (not reached, 97–NE; hazard ratio 0·53, 95% CI 0·44–0·64, p<0·0001). 6-year metastasis-free survival was 82% (95% CI 79–85) in the combination-therapy group and 69% (66–72) in the control group. There was no evidence of a difference in metatasis-free survival when enzalutamide and abiraterone acetate were administered concurrently compared with abiraterone acetate alone (interaction HR 1·02, 0·70–1·50, p=0·91) and no evidence of between-trial heterogeneity (I2 p=0·90). Overall survival (median not reached [IQR NE–NE] in the combination-therapy groups vs not reached [103–NE] in the control groups; HR 0·60, 95% CI 0·48–0·73, p<0·0001), prostate cancer-specific survival (not reached [NE–NE] vs not reached [NE–NE]; 0·49, 0·37–0·65, p<0·0001), biochemical failure-free-survival (not reached [NE–NE] vs 86 months [83–NE]; 0·39, 0·33–0·47, p<0·0001), and progression-free-survival (not reached [NE–NE] vs not reached [103–NE]; 0·44, 0·36–0·54, p<0·0001) were also significantly longer in the combination-therapy groups than in the control groups. Adverse events grade 3 or higher during the first 24 months were, respectively, reported in 169 (37%) of 451 patients and 130 (29%) of 455 patients in the combination-therapy and control groups of the abiraterone trial, respectively, and 298 (58%) of 513 patients and 172 (32%) of 533 patients of the combination-therapy and control groups of the abiraterone and enzalutamide trial, respectively. The two most common events more frequent in the combination-therapy groups were hypertension (abiraterone trial: 23 (5%) in the combination-therapy group and six (1%) in control group; abiraterone and enzalutamide trial: 73 (14%) and eight (2%), respectively) and alanine transaminitis (abiraterone trial: 25 (6%) in the combination-therapy group and one (<1%) in control group; abiraterone and enzalutamide trial: 69 (13%) and four (1%), respectively). Seven grade 5 adverse events were reported: none in the control groups, three in the abiraterone acetate and prednisolone group (one event each of rectal adenocarcinoma, pulmonary haemorrhage, and a respiratory disorder), and four in the abiraterone acetate and prednisolone with enzalutamide group (two events each of septic shock and sudden death).


Among men with high-risk non-metastatic prostate cancer, combination therapy is associated with significantly higher rates of metastasis-free survival compared with ADT alone. Abiraterone acetate with prednisolone should be considered a new standard treatment for this population.


Cancer Research UK, UK Medical Research Council, Swiss Group for Clinical Cancer Research, Janssen, and Astellas.


  1. 1.
    • Helgstrand JT 
    • Røder MA 
    • Klemann N 
    • et al.
    Diagnostic characteristics of lethal prostate cancer.
    Eur J Cancer. 2017; 84: 18-26
  2. 2.
    • Roy S 
    • Morgan SC
    Who dies from prostate cancer? An analysis of the Surveillance, Epidemiology and End Results Database.
    Clin Oncol (R Coll Radiol). 2019; 31: 630-636
  3. 3.
    • Bolla M 
    • Gonzalez D 
    • Warde P 
    • et al.
    Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin.
    N Engl J Med. 1997; 337: 295-300
  4. 4.
    • Widmark A 
    • Klepp O 
    • Solberg A 
    • et al.
    Endocrine treatment, with or without radiotherapy, in locally advanced prostate cancer (SPCG-7/SFUO-3): an open randomised phase III trial.
    Lancet. 2009; 373: 301-308
  5. 5.
    • Warde P 
    • Mason M 
    • Ding K 
    • et al.
    Combined androgen deprivation therapy and radiation therapy for locally advanced prostate cancer: a randomised, phase 3 trial.
    Lancet. 2011; 378: 2104-2111
  6. 6.
    • Bolla M 
    • de Reijke TM 
    • Van Tienhoven G 
    • et al.
    Duration of androgen suppression in the treatment of prostate cancer.
    N Engl J Med. 2009; 360: 2516-2527
  7. 7.
    • James ND 
    • de Bono JS 
    • Spears MR 
    • et al.
    Abiraterone for prostate cancer not previously treated with hormone therapy.
    N Engl J Med. 2017; 377: 338-351
  8. 8.
    • Armstrong AJ 
    • Szmulewitz RZ 
    • Petrylak DP 
    • et al.
    ARCHES: a randomized, phase III study of androgen deprivation therapy with enzalutamide or placebo in men with metastatic hormone-sensitive prostate cancer.
    J Clin Oncol. 2019; 37: 2974-2986
  9. 9.
    • Chi KN 
    • Agarwal N 
    • Bjartell A 
    • et al.
    Apalutamide for metastatic, castration-sensitive prostate cancer.
    N Engl J Med. 2019; 381: 13-24
  10. 10.
    • Davis ID 
    • Martin AJ 
    • Stockler MR 
    • et al.
    Enzalutamide with standard first-line therapy in metastatic prostate cancer.
    N Engl J Med. 2019; 381: 121-131
  11. 11.
    • Fizazi K 
    • Tran N 
    • Fein L 
    • et al.
    Abiraterone plus prednisone in metastatic, castration-sensitive prostate cancer.
    N Engl J Med. 2017; 377: 352-360
  12. 12.
    • Sweeney CJ 
    • Chen YH 
    • Carducci M 
    • et al.
    Chemohormonal therapy in metastatic hormone-sensitive prostate cancer.
    N Engl J Med. 2015; 373: 737-746
  13. 13.
    • James ND 
    • Sydes MR 
    • Clarke NW 
    • et al.
    Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial.
    Lancet. 2016; 387: 1163-1177
  14. 14.
    • Sandler HM 
    • Karrison T 
    • Sartor AO 
    • et al.
    Adjuvant docetaxel for high-risk localized prostate cancer: update of NRG Oncology/RTOG 0521.
    Proc Am Soc Clin Oncol. 2020; 38 (abstr).: 333
  15. 15.
    • James ND 
    • Ingleby FC 
    • Clarke NW 
    • et al.
    855PD - docetaxel for hormone-naïve prostate cancer (PCa): results from long-term follow-up of non-metastatic (M0) patients in the STAMPEDE randomised trial.
    Ann Oncol. 2019; 30: v331
  16. 16.
    • Fizazi K 
    • Carmel A 
    • Joly F 
    • et al.
    Updated results of GETUG-12, a phase III trial of docetaxel-based chemotherapy in high-risk localized prostate cancer, with a 12-year follow-up.
    Ann Oncol. 2018; 29viii271
  17. 17.
    • Attard G 
    • Reid AH 
    • Yap TA 
    • et al.
    Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven.
    J Clin Oncol. 2008; 26: 4563-4571
  18. 18.
    • Attard G 
    • Merseburger AS 
    • Arlt W 
    • et al.
    Assessment of the safety of glucocorticoid regimens in combination with abiraterone acetate for metastatic castration-resistant prostate cancer: a randomized, open-label phase 2 study.
    JAMA Oncol. 2019; 5: 1159-1167
  19. 19.
    • Scher HI 
    • Beer TM 
    • Higano CS 
    • et al.
    Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1–2 study.
    Lancet. 2010; 375: 1437-1446
  20. 20.
    • Morris MJ 
    • Heller G 
    • Bryce AH 
    • et al.
    Alliance A031201: a phase III trial of enzalutamide (ENZ) versus enzalutamide, abiraterone, and prednisone (ENZ/AAP) for metastatic castration resistant prostate cancer (mCRPC).
    Proc Am Soc Clin Oncol. 2019; 375008
  21. 21.
    • Efstathiou E 
    • Boukovala MA 
    • Spetsieris N 
    • et al.
    Neoadjuvant apalutamide (APA) plus leuprolide (LHRHa) with or without abiraterone (AA) in localized high-risk prostate cancer (LHRPC).
    Proc Am Soc Clin Oncol. 2020; 385504
  22. 22.
    • McKay RR 
    • Ye H 
    • Xie W 
    • et al.
    Evaluation of intense androgen deprivation before prostatectomy: a randomized phase II trial of enzalutamide and leuprolide with or without abiraterone.
    J Clin Oncol. 2019; 37: 923-931
  23. 23.
    • Saad F 
    • Efstathiou E 
    • Attard G 
    • et al.
    Apalutamide plus abiraterone acetate and prednisone versus placebo plus abiraterone and prednisone in metastatic, castration-resistant prostate cancer (ACIS): a randomised, placebo-controlled, double-blind, multinational, phase 3 study.
    Lancet Oncol. 2021; 22: 1541-1549
  24. 24.
    • Attard G 
    • Borre M 
    • Gurney H 
    • et al.
    Abiraterone alone or in combination with enzalutamide in metastatic castration-resistant prostate cancer with rising prostate-specific antigen during enzalutamide treatment.
    J Clin Oncol. 2018; 36: 2639-2646
  25. 25.
    • Xie W 
    • Regan MM 
    • Buyse M 
    • et al.
    Metastasis-free survival is a strong surrogate of overall survival in localized prostate cancer.
    J Clin Oncol. 2017; 35: 3097-3104
  26. 26.
    • Clarke NW 
    • Ali A 
    • Ingleby FC 
    • et al.
    Addition of docetaxel to hormonal therapy in low- and high-burden metastatic hormone sensitive prostate cancer: long-term survival results from the STAMPEDE trial.
    Ann Oncol. 2019; 30: 1992-2003
  27. 27.
    • Hoyle AP 
    • Ali A 
    • James ND 
    • et al.
    Abiraterone in “high-” and “low-risk” metastatic hormone-sensitive prostate cancer.
    Eur Urol. 2019; 76: 719-728
  28. 28.
    • Attard G 
    • Brown LC 
    • Clarke NW 
    • Parmar MKB 
    • James ND
    Should patients with high-risk localised or locally advanced prostate cancer receive abiraterone acetate in addition to androgen deprivation therapy? Update on a planned analysis of the STAMPEDE trial.
    Eur Urol. 2021; 80: 522-523
  29. 29.
    • Park JJH 
    • Siden E 
    • Zoratti MJ 
    • et al.
    Systematic review of basket trials, umbrella trials, and platform trials: a landscape analysis of master protocols.
    Trials. 2019; 20: 572
  30. 30.
    • Parker CC 
    • James ND 
    • Brawley CD 
    • et al.
    Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trial.
    Lancet. 2018; 392: 2353-2366
  31. 31.
    • Mason MD 
    • Clarke NW 
    • James ND 
    • et al.
    Adding celecoxib with or without zoledronic acid for hormone-naive prostate cancer: long-term survival results from an adaptive, multiarm, multistage, platform, randomized controlled trial.
    J Clin Oncol. 2017; 35: 1530-1541

Related Audio

Plaats een reactie ...

Reageer op "Abiraterone plus hormoontherapie (ADT) geeft bij mannen met hoogrisico niet uitgezaaide prostaatkanker betere uitzaaiingsvrije overleving vergeleken met alleen hormoontherapie"

Gerelateerde artikelen

Gerelateerde artikelen

PARP-remmer niraparib toegevoegd >> Abiraterone plus hormoontherapie >> Abiraterone naast standaardbehandeling >> Apalutamide en abiraterone >> Abiraterone zonder hormoontherapie >> abiraterone acetate (Zytiga) >> abiraterone acetate (Zytiga) >> Abiraterone Acetate geeft >> Abiraterone Acetate door FDA >>